In 2013, the U.S. Supreme Court issued a landmark decision, FTC v. Actavis, in which it ordered the lower courts to apply the rule of reason to “reverse payment settlement agreements.” As the leading jurisdiction for antitrust and intellectual property laws, the United States is once again poised to influence foreign jurisdictions on the issue of reverse payment settlement agreements. In this context, South Korea presents a ripe opportunity for a comparative study because it recently adopted a patent-approval linkage system under which reverse payment settlement agreements will likely become a contentious issue. In particular, the South Korean Supreme Court’s recent case, GlaxoSmithKline v. Korea Fair Trade Commission, offers valuable insig...
An imminent US Supreme Court ruling should resolve one of the thorniest legal issues facing pharmace...
The complexities of international intellectual property litigation (including jurisdictional issues,...
This thesis focuses on so-called “reverse payment patent settlements” or “pay-for-delay settlements”...
In 2013, the U.S. Supreme Court issued a landmark decision, FTC v. Actavis, in which it ordered the ...
The term reverse payment has been used as shorthand to characterize a variety of diverse agreement...
??????????????????????????????????????????????????? ?????????????????? ??????-??????????????????????...
Paragraph IV of the Hatch-Waxman Act provides a mechanism for litigating pharmaceutical patent infri...
Reverse payment settlements have ignited a firestorm debate among all affected parties: consumer gro...
Reverse payment settlements have attracted increased scrutiny due to the controversial presence of a...
In FTC v. Actavis, the Supreme Court determined that courts should apply a rule of reason analysis t...
Within the tool-box developed by originator companies in order to prepare and respond to generic en...
The aim of the paper is to analyse the issue of reverse payment agreements concluded in a context of...
The aim of the paper is to analyse the issue of reverse payment agreements concluded in a context of...
South Korea has historically restricted foreign entry into its domestic legal services market, but h...
Several federal courts of appeal have recently ruled on the issue of whether a pharmaceutical patent...
An imminent US Supreme Court ruling should resolve one of the thorniest legal issues facing pharmace...
The complexities of international intellectual property litigation (including jurisdictional issues,...
This thesis focuses on so-called “reverse payment patent settlements” or “pay-for-delay settlements”...
In 2013, the U.S. Supreme Court issued a landmark decision, FTC v. Actavis, in which it ordered the ...
The term reverse payment has been used as shorthand to characterize a variety of diverse agreement...
??????????????????????????????????????????????????? ?????????????????? ??????-??????????????????????...
Paragraph IV of the Hatch-Waxman Act provides a mechanism for litigating pharmaceutical patent infri...
Reverse payment settlements have ignited a firestorm debate among all affected parties: consumer gro...
Reverse payment settlements have attracted increased scrutiny due to the controversial presence of a...
In FTC v. Actavis, the Supreme Court determined that courts should apply a rule of reason analysis t...
Within the tool-box developed by originator companies in order to prepare and respond to generic en...
The aim of the paper is to analyse the issue of reverse payment agreements concluded in a context of...
The aim of the paper is to analyse the issue of reverse payment agreements concluded in a context of...
South Korea has historically restricted foreign entry into its domestic legal services market, but h...
Several federal courts of appeal have recently ruled on the issue of whether a pharmaceutical patent...
An imminent US Supreme Court ruling should resolve one of the thorniest legal issues facing pharmace...
The complexities of international intellectual property litigation (including jurisdictional issues,...
This thesis focuses on so-called “reverse payment patent settlements” or “pay-for-delay settlements”...